This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2011 May;8(5):253.

doi: 10.1038/nrclinonc.2011.38.

Combination therapy: A confirmed first-line option for CLL

PMID: 21451466
DOI: 10.1038/nrclinonc.2011.38

Comment

Combination therapy: A confirmed first-line option for CLL

Rebecca Kirk. Nat Rev Clin Oncol. 2011 May.

. 2011 May;8(5):253.

doi: 10.1038/nrclinonc.2011.38.

Author

PMID: 21451466
DOI: 10.1038/nrclinonc.2011.38

No abstract available

PubMed Disclaimer

Comment on

Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712.
Woyach JA, Ruppert AS, Heerema NA, Peterson BL, Gribben JG, Morrison VA, Rai KR, Larson RA, Byrd JC. Woyach JA, et al. J Clin Oncol. 2011 Apr 1;29(10):1349-55. doi: 10.1200/JCO.2010.31.1811. Epub 2011 Feb 14. J Clin Oncol. 2011. PMID: 21321292 Free PMC article. Clinical Trial.

References

1. J Clin Oncol. 2011 Apr 1;29(10):1349-55 - PubMed

Publication types

Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
- Ovid Technologies, Inc.